Summary
This report aims to analyze the current and future potential of cancer vaccines by examining key fundamentals across the entire pipeline of cancer vaccine drug candidates. BioSeeker has identified three fundamental dimensions to outline the competitive landscape within the pharmaceutical industry; compound type, therapy area and target type. For the purposes of this report, BioSeeker is focusing on therapeutic cancer vaccines and as such the commercialized and pipeline prophylactic agents have not been included.
This report is written for you to identify your competition and understand which targeting strategies are at work within cancer vaccine drug development. It allows you to pin-point which competitors drugs' clinical out-come may have bearing on your own drug development and who are developing sequels to blockbuster drugs. This report also helps you to locate white-spots in the competitive landscape, giving you little or no competition. Conversly it may reveal unexpected competition for you.
Drug targets are the critical link between drugs and their role in the treatment of medical disorders. BioSeeker has surveyed cancer vaccines and identified 75 drug targets belonging to 109 drugs. This report, Cancer Vaccine: Aim and Shoot, is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of cancer vaccine drugs.
In the report, BioSeeker reports on 66 unique drug target combinations, each comprised of a different collection or mix of individually defined targets, for 109 cancer vaccine drugs designed for the treatment of 37 different cancer indications. The highest degree of distinctiveness among cancer vaccine drugs is achieved by sorting each of them according to targeted cancer indication, drug target mix, and drug compound type. At the same time we are also identifying peer groups of drugs, that is, drugs we consider suitable for head-to-head comparison during drug development.
To fuel the scientific and competitive thinking, BioSeeker opens the gate into the presence and relevance of protein-protein interactions between identified targets of cancer vaccine drugs. No less than 64 protein-protein interactions were recognized among and between 41 of the 75 included cancer vaccine drug targets.
Why You Should Own Your Own Copy of this Report:
- 180+ pages, with almost a hundred different tables and figures. Includes more than 1,000 active links to related resources on the Internet
- A 109 cancer vaccine drugs analysis, under development by 76 investigators, covering more than 236 developmental projects in cancer
- 75 unique, in-depth, drug target profiles, highlighting twelve themes about the drug target, i.e. protein-protein interaction with other drug targets, pursued cancer indications, drugs under development, compound types, presence in the Cancer Genome Project etc.
- A unique drug target combination breakdown of cancer vaccines into tumor type, compound type, and developmental stage
- Unique drug-protein target and protein-protein of drug targets interactome analysis
- Pathway profiling of cancer vaccine drug targets
- Pin-point which competitor drugs' clinical out-come may have bearing on your own drug development
- Who are working on sequels to blockbuster drugs?
- Locate white-spots in the competitive landscape, giving you little or no competition
In all, this report is a serious reference for any professional interested in the development of oncology drug targets and the selection/validation of targeting strategies.
|
